Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

MINOCIN Drug Profile

« Back to Dashboard
Minocin is a drug marketed by Triax Pharms, Lederle, Rempex Pharms Inc, and Precision Dermat. and is included in five NDAs. It is available from four suppliers. There are two patents protecting this drug.

This drug has fifteen patent family members in fourteen countries.

The generic ingredient in MINOCIN is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Forty-six suppliers are listed for this compound. There are six tentative approvals for this compound. Additional details are available on the minocycline hydrochloride profile page.

Summary for Tradename: MINOCIN

Suppliers / Packagers: see list4
Drug Prices: :see details

Pharmacology for Tradename: MINOCIN

Drug ClassTetracycline-class Drug

Clinical Trials for: MINOCIN

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Triax Pharms
minocycline hydrochloride
CAPSULE;ORAL050315-002Approved Prior to Jan 1, 1982DISCNNo
Precision Dermat
minocycline hydrochloride
CAPSULE;ORAL050649-001May 31, 1990RXNo
Rempex Pharms Inc
minocycline hydrochloride
INJECTABLE;INJECTION050444-001Approved Prior to Jan 1, 1982RXYes9,278,105May 12, 2031
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MINOCIN

Country Document Number Estimated Expiration
Colombia6650346<disabled in preview>
European Patent Office2568987<disabled in preview>
World Intellectual Property Organization (WIPO)2011143503<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.